Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 1,204,924	$ 602,562
Marketable securities	640,460	620,167
Accounts receivable, net	1,292,445	824,406
Due from unconsolidated joint business, net	283,360	252,662
Inventory	804,022	659,003
Other current assets	447,462	226,134
Total current assets	4,672,673	3,184,934
Marketable securities	1,470,652	625,772
Property, plant and equipment, net	1,765,683	1,750,710
Intangible assets, net	4,028,507	4,474,653
Goodwill	1,760,249	1,232,916
Investments and other assets	618,795	594,350
Total assets	14,316,559	11,863,335
Current liabilities:
Current portion of notes payable	3,136	3,494
Taxes payable	168,058	179,685
Accounts payable	229,178	219,913
Accrued expenses and other	1,819,334	1,355,187
Total current liabilities	2,219,706	1,758,279
Notes payable	582,061	592,433
Long-term deferred tax liability	50,656	232,554
Other long-term liabilities	650,096	659,231
Total liabilities	3,502,519	3,242,497
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0	0
Common stock, par value $0.0005 per share	129	128
Additional paid-in capital	4,196,156	4,023,651
Accumulated other comprehensive loss	(59,488)	(27,745)
Retained earnings	9,283,919	6,349,135
Treasury stock, at cost; 22,562 shares and 19,641 shares, respectively	(2,611,706)	(1,724,927)
Total Biogen Idec Inc. shareholders’ equity	10,809,010	8,620,242
Noncontrolling interests	5,030	596
Total equity	10,814,040	8,620,838
Total liabilities and equity	$ 14,316,559	$ 11,863,335